Subcutaneously administered anti-IL-6 receptor antibody
The present application concerns methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.
1. A method of decreasing Disease Activity Score 28 (DAS28) in a rheumatoid arthritis patient comprising subcutaneously administering to the patient a fixed dose of 162 mg of tocilizumab from a single pre-filled syringe subcutaneous administration device which contains and delivers to the patient 0.9 mL of a liquid formulation comprising tocilizumab at a concentration of 180 mg/mL and no hyaluronidase, wherein the 162 mg fixed dose is administered every week or every two weeks to the patient, and wherein the subcutaneous administration of tocilizumab decreases DAS28 to <2.6 at week 24 in the patient.
2. The method of claim 1 wherein the 162 mg fixed dose is administered every week.
3. The method of claim 1 wherein the 162 mg fixed dose is administered every two weeks.
4. The method of claim 1 wherein the patient is a TNF inhibitor inadequate responder.
5. The method of claim 1 further comprising administering a non-biological disease modifying anti-rheumatic drug (DMARD) to the patient during the treatment.
6. The method of claim 5 comprising administering a non-biological DMARD other than methotrexate to the patient during the treatment.
7. The method of claim 5 comprising administering methotrexate to the patient during the treatment.
8. The method of claim 1 wherein methotrexate is not administered to the patient during the treatment.
9. A method of treating a rheumatoid arthritis patient comprising subcutaneously administering to the patient a fixed dose of 162 mg of tocilizumab from a single pre-filled syringe subcutaneous administration device which contains and delivers to the patient 0.9 mL of a liquid formulation comprising tocilizumab at a concentration of 180 mg/mL and no hyaluronidase, wherein the 162 mg fixed dose is administered every week or every two weeks to the patient, and wherein the subcutaneous administration of tocilizumab is effective for treating the rheumatoid arthritis in the patient.
10. The method of claim 9 wherein the patient has American College of Rheumatology (ACR) ACR20 response, ACR50 response, ACR70 response, ACR-hybrid response, or reduced disease activity score 28 (DAS28), at week 24 or week 48.
11. The method of claim 9 wherein the patient has reduced DAS28 compared with baseline at week 24.
12. The method of claim 11 wherein the patient has DAS28<2.6 at week 24.
13. The method of claim 9 wherein the 162 mg fixed dose is administered every week.
14. The method of claim 9 wherein the 162 mg fixed dose is administered every two weeks.
15. The method of claim 9 wherein the patient is a TNF inhibitor inadequate responder.
16. The method of claim 9 further comprising administering a non-biological disease modifying anti-rheumatic drug (DMARD) to the patient during the treatment.
17. The method of claim 16 comprising administering a non-biological DMARD other than methotrexate to the patient during the treatment.
18. The method of claim 16 comprising administering methotrexate to the patient during the treatment.
19. The method of claim 9 wherein methotrexate is not administered to the patient during the treatment.
20. A method of decreasing Disease Activity Score 28 (DAS28) in a rheumatoid arthritis patient comprising subcutaneously administering to the patient a fixed dose of 162 mg of tocilizumab without methotrexate from a single pre-filled syringe subcutaneous administration device wherein the device contains and delivers to the patient 0.9 mL of a liquid formulation comprising tocilizumab at a concentration of 180 mg/mL and no hyaluronidase, and wherein the 162 mg fixed dose is administered every week or every two weeks to the patient, and wherein the subcutaneous administration of tocilizumab without methotrexate decreases DAS28 to <2.6 at week 24 in the patient.
21. The method of claim 20 wherein the patient is a TNF inhibitor inadequate responder.
22. The method of claim 20 wherein the 162 mg fixed dose is administered every week.
23. The method of claim 20 wherein the 162 mg fixed dose is administered every two weeks.